surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Tirzepatide maintains weight loss in

Some individuals report feeling full sooner during meals, less interest in snacking, or reduced cravings for high-calorie foods

Your stomach releases food into the small intestine much more slowly than normal

The battery provided an age-adjusted composite scores of overall cognition 56 for each test session based on seven cognitive function tests: a flanker inhibitory control and attention test 57 , a picture sequence memory test 58 , a list sorting working memory test 59 , a picture vocabulary test 60 , an oral reading recognition test 60 , dimensional change card sort test 57 and a pattern comparison processing speed test 61

Individual Safety Profile: Suitability depends on diagnosis, medical history, current medications, and clinician evaluation

Presented for research literature review only Aydemir T et al